Login to Your Account



Adcom: Safety Profile Is Not a Knockout for Lemtrada

By Mari Serebrov
Washington Editor

Wednesday, November 13, 2013
Despite misgivings about the adequacy and controls of two open-label Phase III trials in evaluating Genzyme Corp.’s Lemtrada in relapsing-remitting MS, the Peripheral and Central Nervous System Drugs Advisory Committee seemed to support approval of the drug, but not as a first-line therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription